April 2025 ACIP Recommendations and Other Updates

Author(s):

Adam James, PharmD

A panelist discusses recent advancements in the respiratory syncytial virus (RSV) vaccine space, including the approval of Arexvy and Abrysvo for older adults and pregnant individuals, the development of promising mRNA and protein subunit vaccines for high-risk groups, and ongoing studies to optimize dosing schedules and booster needs, all aimed at reducing RSV-related hospitalizations and deaths.

EP: 1.The Impact of Respiratory Syncytial Virus (RSV) on Vulnerable Populations

EP: 2.Identifying Candidates for RSV Vaccination

EP: 3.Key RSV Vaccines

EP: 4.The Role of Community Pharmacists in RSV Vaccine Uptake

EP: 5.RSV Vaccination Tools and Resources for Pharmacists

EP: 6.Educating Patients About Adverse Events in RSV

Now Viewing

EP: 7.April 2025 ACIP Recommendations and Other Updates

EP: 8.Key Takeaways to Prioritize in Practice

Summary for Physicians:

Recent advancements in the RSV vaccine space include the following:

Vaccine Approvals:
1. Arexvy (GSK) and Abrysvo (Pfizer, Inc) have been approved for use in older adults (60 years and older) and pregnant individuals, offering protection to both adults and newborns through maternal antibodies.
Vaccine Platforms:
1. mRNA and protein subunit vaccines are showing promising results, particularly for high-risk groups such as infants, older adults, and immunocompromised individuals.
Efficacy & Safety:
1. Clinical trials demonstrate high efficacy in reducing severe RSV disease, with mild adverse effects such as injection site soreness and mild fever.
Future Outlook:
1. Ongoing studies aim to optimize dosing schedules and assess booster needs, with a focus on reducing RSV-related hospitalizations and deaths in vulnerable populations.

These advancements provide new options for protecting high-risk patients from RSV infection.